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S U M M A R Y
Background: In October 2006, a rotavirus vaccine was introduced in Nicaragua for routine immunization
of all children. We document the baseline diarrheal disease burden in Nicaragua prior to the vaccine
program to facilitate future studies to measure vaccine impact.
Methods: We analyzed national data for 2001–2005 on total acute gastroenteritis healthcare visits,
hospitalizations, and mortality in Nicaraguan children aged <5 years.
Results: Prior to vaccine introduction, by age 5 years, one in four Nicaraguan children required an
outpatient consultation, one in 34 were hospitalized, and one in 2487 died from rotavirus-associated
diarrhea, representing approximately 41 122 outpatient visits, 4460 hospitalizations, and 60 deaths per
year that are preventable through vaccination. Almost half of the total acute gastroenteritis burden
was in children <1 year of age. Two distinct seasonal peaks were noted in acute gastroenteritis
hospitalizations and deaths.
Conclusions: Existing data sources on all-cause acute gastroenteritis could be useful for establishing
diarrhea disease burden and monitoring trends after vaccine introduction. Blunting of winter season
peaks in rates of diarrhea, particularly among children aged <1–2 years, would be a useful indicator of
impact from rotavirus vaccination.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Rotavirus, the most common cause of severe gastroenteritis in
children aged <5 years worldwide, accounts for an estimated 2.4
million hospital admissions and 527 000 deaths each year.1,2 The
tremendous global burden of rotavirus has prompted the
prioritization of vaccine development and introduction by several
international agencies, including the World Health Organization
(WHO) and the Global Alliance for Vaccines and Immunizations
(GAVI).3 Two new rotavirus vaccines with good efﬁcacy against
severe rotavirus disease – RotaTeq1 (Merck Vaccines, Whitehouse
Station, NJ, USA) and Rotarix1 (GlaxoSmithKline Biologicals,§ The ﬁndings and conclusions in this report are those of the authors and do not
necessarily represent the views of the Centers for Disease Control and Prevention
(CDC).
* Corresponding author. Tel.: +1 404 639 2343; fax: +1 404 639 3607.
E-mail address: Aul3@CDC.GOV (M. Patel).
1201-9712/$36.00 – see front matter . Published by Elsevier Ltd on behalf of Internatio
doi:10.1016/j.ijid.2009.08.014Rixensart, Belgium) – have recently been licensed for use in many
countries.4,5 Low and middle income countries in the Latin
American region have been among the ﬁrst to add new rotavirus
vaccines to the routine childhood immunization schedule. As such,
monitoring the trends of diarrheal disease before and after vaccine
introduction in these regions will be crucial to assess impact and
gather the necessary data for decision-makers to use in evaluating
and sustaining a vaccination program.
In October 2006, a rotavirus vaccine (RotaTeq) was added to the
national vaccination schedule in Nicaragua, after a large nation-
wide outbreak of rotavirus diarrhea in 2005 led to an unexpected
increase in diarrhea mortality, hospitalizations, and outpatient
visits and garnered substantial attention from decision-makers
and public health authorities in Nicaragua.6,7 In response to the
recent rotavirus vaccine introductions in many countries world-
wide, the WHO has published a generic protocol outlining
approaches to monitoring the impact of rotavirus vaccination on
disease burden.8 Vaccine introduction in Nicaragua provided us an
early opportunity to ﬁeld-test one aspect of this protocol –nal Society for Infectious Diseases.
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burden. As a ﬁrst step in preparing to monitor trends of acute
gastroenteritis in Nicaragua, we examined national data for acute
gastroenteritis hospitalizations and outpatient visits among
children aged <5 years to establish baseline incidence of disease
prior to vaccine introduction, against which acute gastroenteritis
trends can be compared as the vaccine program matures.
2. Methods
Nicaragua is a low income country in Central America with a
gross national income of 980 US dollars per capita and an annual
birth cohort of approximately 150 000 and an infant mortality rate
of 21.5 per 1000 live births.9 In Nicaragua, 21.0% of the population
lives without access to an improved water source and 10.0% of the
children aged <5 years are considered underweight for age.9 A
majority (85.0%) of the population utilize healthcare facilities
operated by the Ministry of Health, which includes 1059
healthcare facilities, including 32 hospitals providing inpatient
services to the population, and 172 health centers and 855 health
posts that provide primary care services. On aweekly basis, each of
the public health centers and hospitals organized into local health
units, report to the Ministry the number of outpatient visits,
hospitalizations, and deaths due to diarrhea. At the Ministry, the
data are compiled in an electronic database. To estimate the
national burden of diarrheal disease leading to outpatient visits,
hospitalization, and death in children <5 years old, we reviewed
the Ministry of Health’s computerized records on total country-
wide reports of acute gastroenteritis from January 2001 to
December 2005. Limited data exist in Nicaragua on the proportion
of severe diarrhea cases attributable to rotavirus disease.
Therefore, we utilized surveillance data from neighboring Hon-
duras10,11 and El Salvador12,13 and a review of rotavirus disease
burden in Latin America14 to estimate the proportion of all-cause
acute gastroenteritis among children <5 years of age attributable
to rotavirus. In the review of studies from Latin America,14 someFigure 1. Cumulative risk of diarrheal- and rotavirus-associated estudies included children <3 and others <5 years of age, however,
the authors did not ﬁnd a difference in detection rates between the
two age groups. In El Salvador and Honduras, active surveillance
indicates rotavirus detection rates of approximately 43% (range in
Latin America:14 16–52%) in the hospital setting, approximately
30% (range 18–42%) in the outpatient setting, and approximately
70% in any setting during the rotavirus season (typically weeks 1–
20). To estimate the annual rotavirus disease burden, we
multiplied the annual number of acute gastroenteritis visits
among children aged <5 years by setting with these rotavirus
detection rates of 43% (hospitalized children) and 30% (outpatient
visits). Subsequently, we calculated the cumulative risk that a child
would experience these events (outpatient visit, hospitalization, or
death) before reaching the age of 5 years. Cumulative risks were
expressed as the inverse of the annual birth cohort (n  150 000)
divided by the respective median number of events among
children <5 years of age from 2001 through 2005. Finally, to
illustrate temporal and seasonal trends in diarrheal visits, we
plotted the 2001–2005 weekly mean of total gastroenteritis for
children<5 years of age. Data for the year 2006 were not available
because of a nationwide healthcare worker strike during the ﬁrst
six months of the year.
3. Results
Among children <5 years old, the Ministry computerized
records for public health facilities identiﬁed an annual median of
137 074 non-hospital consultations (range 129 418–147 878), 10
373 hospitalizations (range 8623–13 083), and 140 in-hospital
deaths (range 78–178) for diarrhea (Figure 1). Thus, prior to
rotavirus vaccine introduction in Nicaragua, by age 5 every child
required an outpatient consultation, one in 14 were hospitalized,
and one in 1069 died as a result of diarrhea.
In neighboring countries, active surveillance indicates rotavirus
detection rates of approximately 43% in the hospitalized setting
and approximately 30% in the outpatient setting.6,10,11,13,14vents for all children aged <5 years—Nicaragua, 2001–2005a.
Figure 2. Total acute gastroenteritis events in children aged 11 months and 12–59 months old, by week—Nicaragua 2001–2005.
Figure 3. Total acute gastroenteritis-associated deaths in children aged <5 years during 2001–2005, by weeks of year.
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assuming the fraction of diarrhea deaths attributable to rotavirus is
similar to that for hospitalizations, we estimate rotavirus-
associated diarrhea in children <5 years old to annually result
in 41 122 outpatient visits (range 38 825–44 363), 4460
hospitalizations (range 3708–5626), and 60 deaths (range 34–
77). Cumulative risks were approximately 1:4 for consultation,
1:34 for hospitalization, and 1:2487 for death by the ﬁfth birthday
(Figure 1).
Examination of total acute gastroenteritis non-hospital con-
sultations and hospitalizations over the ﬁve year study period
showed two distinct seasonal peaks, one during the winter–spring
months of February through May and a larger peak during the
summer (June through September) months (Figure 2). Almost half
of the total gastroenteritis burden was among children <1 year of
age. In 2005, thewinter–spring peakwas substantially greater than
in each of the previous four years, with an increase in number of
events of 10% for <1-year-olds and 12% for 1–5-year-olds.
Trends of in-hospital mortality from acute gastroenteritis
among children <5 years of age also had a similar bi-annual
seasonality (Figure 3). Because rotavirus is suspected to be
responsible for a majority of the severe diarrhea events during
weeks 1–20 in Central America,13,15 the peak in diarrhea mortality
during these weeks is also likely to be associated with rotavirus.4. Discussion
Our data indicate that Nicaragua, given its high diarrhea disease
burden, represents a vital opportunity to improve childhood health
through a new vaccine program that has the potential to
substantially decrease the morbidity, mortality, and healthcare
costs associated with rotavirus disease. Prior to vaccine introduc-
tion, we estimate that each year 41 122 outpatient visits, 4460
hospitalizations, and 60 deaths from rotavirus occurred among
children aged<5 years in Nicaragua. In other words, assuming that
these episodes are independent infections among separate
children, by age 5, approximately 28% of children born in
Nicaragua would have visited a Ministry clinic for treatment of
an episode of rotavirus diarrhea, one in 34 would be hospitalized,
and one in 2487 would have died from rotavirus disease. The fact
that half of the burden of gastroenteritis is in children <1 year of
age, with high vaccine coverage and under assumptions of similar
vaccine efﬁcacy as in the clinical trial, the impact from vaccination
would be notable in children <1–2 years of age after the ﬁrst 2–3
years of vaccine introduction.
By examination of existing Ministry data, our ﬁndings indicate
that it will be possible to discern the impact of vaccination,
although careful analysis and interpretation will be required. The
overall annual reduction in diarrhea-associated medical outcomes
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matures and such a decline could be masked by annual secular
variation in natural disease trends. However, examination of
disease trends during the winter–spring months when rotavirus is
most prevalent and overall reductions in all-cause gastroenteritis
are likely to be greater, could allow for more speciﬁc assessment of
the impact of vaccine in reducing rotavirus events. Furthermore,
the impact of vaccination should bemost visible on diarrhea events
in children<1 year and<2 years of age during the ﬁrst 1–3 years of
a vaccine program, and would only extend to older children after
the program matures in the next 4–5 years. Nicaragua and other
countries currently adopting the rotavirus vaccine could monitor
trends in these speciﬁc seasonal- and age-groups to determine the
real-world impact of a new vaccine program.
Based on a global review of the scientiﬁc literature, an
estimated one in ﬁve children require an outpatient visit for
rotavirus disease and one in 65 require hospitalization by age 5
years.2 Our disease burden estimates for Nicaragua are higher than
the global estimate of rates for rotavirus-associated outpatient
visits and hospitalizations. Differences in healthcare-seeking
behavior or access might in part explain this ﬁnding. While the
estimate for in-hospital diarrhea death from our data is
substantially lower than the WHO estimate of 1020 deaths,1 in-
hospital deaths frequently underestimate total deaths from
rotavirus in a community.10,11,13 For example, in Honduras, only
approximately 15% of all diarrhea deaths are reported through
hospital discharge records. By dividing the number of in-hospital
deaths in Nicaragua by 0.15we estimate approximately 400 deaths
from rotavirus diarrhea. Furthermore, the WHO estimate reﬂects
mortality patterns in the early 1990 s, and diarrhea mortality has
declined considerably in many Latin American countries over the
past two decades, which could also in part explain some of the
discrepancy between the two estimates.
Several caveats must be considered when interpreting our
ﬁndings. First, estimates of rotavirus-speciﬁc disease burden in
Nicaragua were not available. The estimates of rotavirus-speciﬁc
diseaseburdenandmortality used in this analysis are extrapolations
from previous studies and surveillance data from neighboring
countries.10,11,13,14 However, our reference rate of 43% for hospi-
talizations attributable to rotavirus is consistent with detection
rates of 42% seen in Nicaragua during an outbreak investigation in
February 2005.6 Although our data do not include private hospitals
and clinics, more than 85% of the Nicaraguan population uses public
facilities that report to the Ministry of Health. The estimates of
children requiring outpatient visits alsomay be overestimates given
the likelihood that childrenmayhave twoormorevisits for the same
infection. In addition, inaccuracies in reporting may occur that
would have led us to under- or overestimate disease burden.
In conclusion, our study demonstrates the signiﬁcant health
burden of rotavirus among Nicaraguan children. Our ﬁndings
suggest that monitoring trends in non-hospital consultations and
hospitalizations for all-cause diarrhea using routinely collected data
could allow assessment of the impact of vaccination, although
careful analyses and interpretation of data is required. Rotavirus-
speciﬁc surveillance and vaccine effectiveness studieswill provide a
more accurate assessment of the public health beneﬁts of
vaccination. Indeed, early post-licensure data from the USA indicate
that the declines in rotavirus disease after vaccine introductions
appear to be substantially greater than expected.16,17 In a recently
conducted study from Nicaragua, we demonstrated that rotavirus
vaccination prevented50% of the rotavirus hospitalizations at four
sentinel hospitals.7 Countries considering rotavirus vaccine intro-
duction will greatly beneﬁt from establishing active surveillance
programs for monitoring rotavirus diarrhea at sentinel hospitals
according to the WHO generic protocol on rotavirus surveillance,
preferably 2–3 years prior to introduction.18Conﬂict of interest
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